The immunogenicity of malignant melanomas has been recognized by the observed recruitment of tumor-specific cytotoxic T-cells (CTL), leading to the identification of several melanoma associated antigen (MAA). However, numerous strategies to treat melanoma with immunotherapy have resulted in only partial success. In this editorial, we discuss recent data related to the ability of tumors to elude immune responses. We therefore discuss different strategies to induce a clinically effective immune response. These approaches include 1) immunostimulation: including peptide/protein based vaccines, dendritic cell vaccines, and adoptive cell transfer; and 2) overcoming immunosuppression, including targeting of checkpoint molecules such as CTLA-4, circumventing the activity of Tregs, and assuring antigen expression by tumor cells (thwarting antigen silencing). Finally, we discuss recent advances in gene therapy, including adoptive therapy with engineered T cell receptors (TCRs). These issues lead to the conclusion that successful immunotherapy in malignant melanoma requires a combination of strategies aimed at both inducing immunostimulation and blocking immunosuppression.
MihmMCJrClementeCGCascinelliN. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest1996; 74:43–47.
2.
BennettWTPandolfiFGroveBHHawesGEBoyleLAKradinRLKurnickJT. Dominant rearrangements among human tumor-infiltrating lymphocytes. Analysis of T-cells derived from 32 patients with melanoma, lung, and renal cell carcinoma. Cancer1992; 69:2379–2384.
3.
KawakamiYEliyahuSSakaguchiK. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med1994; 180:347–352.
4.
KradinRLBoyleLAPrefferFI. Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunother1987; 24:76–85.
5.
BakkerABSchreursMWde BoerAJKawakamiYRosenbergSAAdemaGJFigdorCG. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med1994; 179:1005–1009.
6.
HishiiMAndrewsDBoyleLAWongJTPandolfiFvan den ElsenPJKurnickJT. In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites. Proc Natl Acad Sci USA1997; 94:1378–1383.
7.
MaeurerMJGollinSMMartinD. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest1996; 98:1633–1641.
8.
PandolfiFBoyleLATrentinLKurnickJTIsselbacherKJGattoni-CelliS. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Cancer Res1991; 51:3164–3170.
9.
ChangCCOginoTMullinsDW. Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. J Biol Chem2006; 281:18763–18773.
10.
LurquinCLetheBDe PlaenE. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med2005; 201:249–257.
11.
RosenbergSASherryRMMortonKE. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol2005; 175:6169–6176.
12.
QuezadaSAPeggsKSCurranMAAllisonJP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest2006; 116:1935–1945.
13.
JuneCH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest2007; 117:1466–1476.
14.
KhongHTRestifoNP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol2002; 3:999–1005.
15.
YeeCThompsonJAByrdD. Adoptive T cell therapy using antigen-specific CD8+ cell clones for the treatment of patients with metastatic melanoma: in vitro persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA2002; 99:16168–73.
16.
DurdaP JDunnISRoseLBButeraDBensonEMPandolfiFKurnickJT. Induction of “antigen silencing” in melanomas by oncostatin M: down-modulation of melanocyte antigen expression. Mol Cancer Res2003; 1:411–419.
17.
DunnISHaggertyTJKonoM. Enhancement of human melanoma antigen expression by IFN-beta. J Immunol2007; 179:2134–2142.
18.
KonoMDunnISDurdaPJ. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol Cancer Res2006; 4:779–792.
19.
GiacominiPGiordaEFraioliR. Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell lines. Cancer Res1999; 59:2657–2667.
20.
RosenbergSA. Progress in human tumour immunology and immunotherapy. Nature2001; 411:380–384.
21.
ParmianiGCastelliCRivoltiniL. Immunotherapy of melanoma. Semin Cancer Biol2003; 13:391–400.
22.
NestleFOAlijagicSGillietM. Vaccination of melanoma patients with peptide- or tumor lysatepulsed dendritic cells. Nat Med1998; 4:328–332.
23.
TerandoAMFariesMBMortonDL. Vaccine therapy for melanoma: current status and future directions. Vaccine2007; 25(S):B4–16.
24.
DudleyMEWunderlichJRYangJC. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol2005; 23:2346–2357.
25.
MeidenbauerNMarienhagenJLaumerMVoglSHeymannJAndreesenRMackensenA. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol2003; 170:2161–2169.
26.
AttiaPPhanGQMakerAVRobinsonMR. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol2005; 23:6043–6053.
27.
DowneySGKlapperJASmithFO. Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade. Clin Cancer Res2007; 13:6681–6688.
28.
O'DaySJHamidOUrbaWJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer2007; 110:2614–27.
29.
WeberJ. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist2007; 12:864–872.
30.
DannullJSuZRizzieriDYangBKColemanDYanceyDZhangADahmPChaoNGilboaEViewegJ. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest2005; 115:3623–3633.
31.
MorganRADudleyMEWunderlichJR. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science2006; 314:126–129.
32.
LuXHumeauLSlepushkinV. Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. J Gene Med2004; 6:963–973.
33.
TsujiTYasukawaMMatsuzakiJ. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood2005; 106:470–476.
34.
Ramirez-MontagutTAndrewsDMIharaA. Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1. Clin Exp Immunol2000; 119:11–18.
35.
KurnickJTRamirez-MontagutTBoyleLA. A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter. J Immunol2001; 167:1204–1211.
